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Abstract. One of the promising methods for the treatment of complex diseases such as
cancer is combinational therapy. Due to the combinatorial complexity, machine learning
models can be useful in this field, where significant improvements have recently been
achieved in determination of synergistic combinations. In this study, we investigate the
effectiveness of different compound representations in predicting the drug synergy. On
a large drug combination screen dataset, we first demonstrate the use of a promising rep-
resentation that has not been used for this problem before, then we propose an ensemble
on representation-model combinations that outperform each of the baseline models.
1 Scientific Background
A drug combination is called synergistic if the effect of the drug combination on
the reference cell is greater than the total effect taken from the administration of the
individual drugs. If the opposite situation is observed, the drug combination is called
antagonistic . Understanding whether a combination is antagonistic or synergistic is a
resource and time intensive task. Developing new synergistic combinations or finding
the best disease-specific combination therapy is also a complex problem, because high
dimensional search space requires searching correct parameters.
Recently, machine learning methods have made significant contributions to the stud-
ies of combination therapies . In this article, we compare three different drug represen-
tation methods to see how they effect predictions of synergy scores and how predictions
change according to these representations and learning models. These representations
are the characteristic direction [1] vectors inferred from drug-induced gene expression
profiles, a chemical fingerprint representation [2] and drug vectors which are learned
directly from molecular graphs by using a graph neural network [3]. We used the target
synergy scores as given in [4] and [2]. In addition, we propose an ensemble method that
outperforms each of the individual methods involved in predicting the synergy score.
There are a number of recent studies for predicting the effect of drug combinations
by using machine learning. NLSS [5] is a work that uses semi-supervised learning to
discover new synergistic drug combinations. Assumption of [5] is that, the more similar
the drugs are to each other, the greater the synergistic effect. Ensemble methods were
also previously used to predict drug synergy score [6]. The authors employed several
well known machine learning algorithms, among which they pick the best performing
four and combined predictions with specific weights to predict actual synergy score esti-
mates. Unlike our study, they worked only on a single representation of drugs. Another
well known ensemble learning method, extremely randomized trees, were applied to this
problem in [7]. Features used in this study are drug-target information, gene expression
and mutation datasets, pharmacological data and synthetic lethality. DeepSynergy [2]
is a fully connected neural network to predict drug synergy. It includes one input layer,
two hidden layers and one output layer. Concatenated drug and cell line features are
given as input. Promising results were obtained with a fully connected architecture. On
the same dataset, [8] applies extreme gradient boosting algorithm. They observed that
this tree based model outperforms the neural networks. In addition, this type of method
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is more explainable than a neural network.
None of above mentioned studies have explored the effect of drug representations for
different algorithms. The ensemble methods mentioned above only consider different
methods not different representations. To our best, this is the first study that investigates
prediction of drug synergy on this context.
The rest of the article is organized as follows. Descriptions of the methods and data
are given in Section 2. Section 3 reports the setting and experimental results. Finally,
we conclude in Section 4 and give some future research directions.
2 Materials and Methods
Drug and cell line representations in addition to the methods employed are explained
in this section. First, we describe the methods for drug synergy score prediction and
then shortly explain the different representations used. The synergy scores were taken
from a large compound oncology dataset [4] which is used for training the model in [2]
where the deviation from a theoretical model of synergy (Loewe additivity in this case)
was calculated and used as the drug synergy score.
2.1 Methods
We used four different single types of models to predict drug synergy scores. These
are classical neural networks, elastic nets, gradient boosted decision trees, random
forests and graph neural networks. Short descriptions of these models follow.
A fully connected neural network (FCNN) is one of the most basic neural network
types. It is the type that is composed of layers where each neuron in layer k is connected
to every node in layer k + 1. The weights of the network is optimized by minimizing
a given error measure through backpropagation algorithm. Note that this is actually the
same model proposed in [2].
Graph embedding is a group of methods to map the graph data to a low dimensional
space . Embedding can be performed for nodes, edges or the whole graph. In this paper,
to construct one of the representations for drugs, we employ whole graph embedding
and use Graph Neural Networks (GNN). GNN is the name given to a group of neural
network methods that can directly operate on a graph input. The specific GNN we use is
the architecture proposed in [3]. We modified this architecture to work with drug pairs
and to estimate the synergy score. First, graph molecules(i.e., r-radius sub-graphs’ atom
types) in each pair are embedded separately in d-length vectors with random weights.
Then, initialized vectors are passed through two separate FCNNs with L layers. Initial-
ized vectors are updated according to graphs’ adjacency matrices when passing through
the L-layered FCNN. Output vectors of the last layers of the L-layered FCNN are the
representations that will be used for prediction. These embeddings combined with the
cell line descriptors can now be used with any learning model that predicts drug synergy.
Elastic net is a regularized linear regression method that uses both L1 and L2 regular-
ization in the target function. Therefore, βi values optimizing, L(α, β) = (y− fˆ(x))2+
(1 − α)∑ni=1 β2i + α∑ni=1 |βi| constitute the model, where βi’s are the parameters of
the linear regression model fˆ .
A Gradient boosting machine (GBM) is an additive model where a weak learner is
fitted to the current residuals at each iteration. At the end, all the predictions from the
weak learners scaled by a small learning rate are added to compute the final prediction.In
this paper, we used decision trees as the weak learners to train a GBM.
Random Forest (RF) is an ensemble algorithm that combines many decision trees
with bootstrap aggregation (bagging) technique and feature sampling. The estimation
of a new instance is performed by computing the average of the responses of all models.
In addition to and using the above methods, we propose an ensemble method com-
posed of ”drug representation-method” combinations as base learners. We used a fixed
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representation for the cell lines (the gene expression profiles) to correctly observe the ef-
fect of drug representations. Among other ensemble learning methods such as stacked
generalization with non-linear learners as the meta learner, weighted linear combina-
tion of the base learners performed best. This method is different from the previously
proposed methods for this problem in the sense that each learner in the ensemble may
use different representations of drugs. The results demonstrate the effectiveness of the
proposed ensemble methodology.
2.2 Cell line and drug representations
In this paper, to represent cell lines, we used the genomics features used in [2]. These
features were obtained by applying Factor Analysis for Robust Microarray Summariza-
tion (FARMS) to the quantile normalized cell line gene expression profiles downloaded
from ArrayExpress database (E-MTAB-3610). At the end of this process, a vector of
length 3984 were obtained as the descriptor of cell lines.
There are three types of drug representations we use. First one is composed of some
of the well known chemical descriptors. Second one employs the drug-induced gene
expression profiles of cell lines and therefore represents a drug by using it’s effects on
gene expression. Finally the last one is a graph neural network method that only uses
the graph topology of drugs to form a representation vector.
The descriptors that we name as the chemical descriptors are the ones used in [2].
In this representation a compound is described as a vector of length 4387 composed of
1309 extended connectivity fingerprint with radius 6 (ECFP 6) features , 802 physico-
chemical features obtained by ChemoPy and 2276 toxicophore features obtained from
the liteature. We will denote this representation as ChemR.
Identification of differentially expressed genes (DEG) is a basic task in gene expres-
sion analysis. Characteristic direction (CD) [1] is a geometric approach to determine
DEG. In [9] CD is computed to identify DEG between normal and drug-induced gene
expression profiles from Library of Integrated Cellular Signatures (LINCS) [10] project.
This CD vector for each drug is of length 978 that comprises of the DEG status of land-
mark genes identified by LINCS. In this paper, as the second representation for drugs,
we employ the CD computed from the normal and drug-induced gene expression data.
The data is available from [9]. We will denote this representation as CDR.
The third drug representation is denoted GNNR, learned by using the GNN with the
structure described in Section 2.1. After this model has been trained, d-length GNNR
representation of any drug can be obtained by using L-layer FCNN which is part of
the architecture of the GNN we used. Since the L-layer FCNN is dependent on the
GNN, the vectors that this structure maps are actually the output of an intermediate
layer of GNN. Thus, the output vectors of this intermediate layer constitutes the GNNR
representation. These vectors, which are created to minimize the error of the FCNN
model, are recorded and used as a representation for compounds.
Using three different representations and four different models mentioned above, we
investigated which representation-model combinations perform better for drug synergy
prediction. In order to accomplish this, first we identified the instances that are common
in all three datasets. Only 29 of the 38 drugs that have ChemR representations are
available within CDR. Instances that do not have CDR data are not included in our study.
Thus, the number of samples we use is 24780 corresponding to these common drugs.
Each of these instances are composed of two drugs and a cell line with a corresponding
synergy score. To compensate the ordering of drugs, the first half of the 24780 feature
vectors are of type drugA-drugB-cell line, where the other half consists of the same
instances with drugs re-ordered (drugB-drugA-cell line), as in [2]. Except GNNR, tanh
normalization is applied to CDR and ChemR similar to [2].
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Table 1: Results for all drug representation-model combinations and proposed ensemble model
MSE Pearson
FCNN GB RF Elas.N. FCNN GB RF Elas.N.
CDR 266.0±57.9 295.8±61.3 405.1±76.6 451.4±76.6 0.74±0.04 0.69±0.03 0.56±0.03 0.47±0.03
ChemR 273.7±53.7 295.2±55.9 410.9±63.5 452.0±77.4 0.72±0.03 0.7±0.03 0.54±0.05 0.47±0.03
GNNR 306.4±55.9 572.5±105.9 578.2±101.8 583.4±103.8 0.69±0.03 0.15±0.01 0.14±0.01 0.11±0.02
Ensemble 260.112±57.144 0.745±0.035
3 Experimental Results
Representation-model combinations were compared according to the scores obtained
as a result of 5-fold cross validation. Cross validation was performed by dividing
datasets with the ”leave drug combinations out” method, as in [2].
We performed parameter optimization for the models on a single validation split.
Hyperparameter tuning search space for gradient boosting and elastic net are selected
according to [8]. For all ensemble tree models, number of estimators is selected as
1000. For CDR and ChemR datasets, in random forest and gradient boosting, maximum
tree depths M ∈ {6, 8}, also in gradient boosting the learning rate T ∈ {0.05, 0.1}.
For GNNR, M ∈ {2, 4}, T ∈ {0.05, 0.01}. For Elastic Net, in all datasets, α ∈
{0.25, 0.5, 0.75, 1.0, 1.15, 1.25, 1.5}. For FCNN, there are five different hyperparame-
ters we optimized; number of nodes in two hidden layers (H), learning rate (F ), dropout
rate (D) and number of epochs (E). There are also three GNN specific parameters, drug
representation dimension (d), radius (r) and the number of layers of L-layered FCNN
(L). For ChemR, H ∈ {{8192, 4096}, {4096, 2048}}, F ∈ {0.0001, 0.00001}. For
CDR, H ∈ {{2500, 3000, 3500}, {1000, 1500, 2000, 2500}}, D ∈ {0.33, 0.4} and E ∈
{350, 500, 455, 200}. For GNNR,H ∈ {{2000, 3000, 4000}, {1000, 1500, 2000}},E ∈
{500, 1000}, d ∈ {25, 50, 100}, r ∈ {2, 3} and L ∈ {3, 4}. Scikit-learn is employed
for Elastic Net and Random Forest models, keras and pytorch are used for GNN and
FCNN models. We utilized xgboost library for gradient boosting.
We can denote each representation-model combination as rm where m is the model
trained on representation r. Parameters that give the best result for CDRFCNN are
E = 455, H = {3000, 1500} and D = 0.4. The best performing parameters for
CDRGB are M = 6 and T = 0.05 as in [8]. The best parameter combination for
ChemRFCNN is the α = 0.00001, H = {8192, 4096}. For ChemRGB, the best param-
eters are M = 6 and T = 0.05. For GNNRFCNN (i.e., GNN ), the best performing
parameters are E = 1000, r = 2, d = 25, L = 3 and H = {3000, 1500}. These are
the parameters selected for the five best representation-model combinations they are the
ones used in our ensemble model. The best parameters for others are not given due to
space restrictions.
To construct the ensemble, we followed a greedy forward selection procedure. The
models, first, are sorted in decreasing order by their mean squared error (MSE). Then,
starting from the top, each model is added to the ensemble one-by-one. With each new
model, we searched for the optimal weights (which are in [0, 1]) of each model in the en-
semble by a grid search procedure. We stopped adding models to the ensemble when we
observe a decrease in performance. This procedure resulted in five representation-model
combinations in the final ensemble, where these models areCDRFCNN ,ChemRFCNN ,
CDRGB, GNNRFCNN and ChemRGB with weights {0.535, 0.19, 0.15, 0.065, 0.06}
respectively.
The results are given in Table 1 in terms of MSE and Pearson correlation (ρ). It is
observed that the proposed ensemble significantly outperforms the other representation-
model (rm) combinations (p < 0.05 for all pairwise comparisons by Wilcoxon signed
rank test). FCNN consistently outperforms all other single models both in terms of MSE
and ρ on all representations. Then comes the GBM, RF and elastic net respectively.
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This gives us a hint that the relationship here is a non-linear one. Our findings here
are also inline with [2] that a neural network model seems to be suitable for this prob-
lem. Also the proposed ensemble model outperforms the DeepSynergy model (given as
ChemRFCNN in our results) proposed in [2].
For representations, the winner is not as clear as the models. In terms of average
MSE for all models, CDR is better than others, while there is no difference between
CDR and ChemR for ρ. GNNR performs poor especially for GBM, RF and elastic net,
only GNNRFCNN is close to others in terms of performance. This is expected as the
GNN model only uses the graph topology as input compared to others that also include
chemical and genomics descriptors. Also, if we look at the individual representation-
model combinations (rm) CDRGB and ChemRGB are not significantly different from
each other (p = 0.753). The situation is also similar for CDRFCNN and ChemRFCNN
(p = 0.115).
Figure 1: difference between the targets and the estimates obtained using CDR data of 100 samples
Figure 2: difference between the targets and the estimates obtained using ChemR data of 100 samples
Figure 3: difference between the targets and the estimates obtained using GNNR data of 100 samples
Figures 1,2 and 3 show a comparison between the estimations obtained using differ-
ent representations with FCNN and actual values of 100 randomly selected samples. It
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can be seen that the results obtained with CDR and ChemR are very similar to each other
where the predictions obtained from both datasets generally achieved the capturing dis-
tribution of target values. On the other hand, it can be observed that the experiment with
GNNR dataset failed to predict the extreme points. For this representation, in general,
estimated values are close to the average of the target values.
To sum up, CDR is a promising representation in terms of performance and com-
putational complexity. However, it may not be available for any compound, as it’s
availability is limited by the LINCS database. In that case, one may use the ChemR rep-
resentation. GNNR is also promising in the sense that it performs close to other models
by only using the graph topology. Finally, it is clear that using both representation and
method ensembles helps improving the prediction of drug synergy.
4 Conclusion
In this paper, we investigated the effect of compound representations on predicting
drug synergy. We employed three different representation types on four different single
models. We demonstrated that a representation summarizing the drug-induced gene ex-
pression profiles may help improving the performance. Also we proposed an ensemble
model that can perform better than each of the baselines, demonstrating the usefulness
of ensemble learning for this type of problems. There are a few directions that we plan
to extend this work. First, we plan to extend the number of model and representation
types. Second, we will work identifying the features that are more important in each of
the representations. This may lead to better understanding the mechanisms underlying
drug synergy.
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